The following risk factors were studied: family history
of SNHL, consanguinity, low birth weight, prematurity, cranio-facial CH5424802 inhibitor abnormality and syndromes associated to SNHL, respiratory distress, intensive care in excess of 5 days (NICU), pregnant maternal diseases, perinatal sepsis or meningitis, hyperbilirubinemia, ototoxic drugs administration.
Results: Forty-seven infants (11.41%) were diagnosed with SNHL; median corrected age at final audiological diagnosis was 12 weeks. SNHL resulted moderate in 44.68%, severe in 10.64% and profound in 21 cases with a significant difference in family history and NICU infants (p < 0.0001). As the number of coexisting risk factors increases, the percentage value of SNHL in infants (chi(2) = 12.31, p = 0.01, r(2) = 0.98) and the degree of hearing loss (chi(2) = 13.40, p = 0.0095, r = 0.92) also increase. The study of single TEOAE and combined TEOAE/ABR showed a statistical difference (chi(2) = 14.89, p < 0.001) with a low concordance value (kappa = 0.87) confirming the importance of combined techniques for NICU group (kappa = 0.86) where four cases (0.97%) of auditory
neuropathy were diagnosed.
Conclusion: This study demonstrates the ACY-1215 manufacturer necessity to implement a neonatal hearing screening program in Western Sicily because of the high percentage of SNHL in infants at risk. Family history of HL is an independent significant risk factor for SNHL easily diagnosed through single TEOAE technique. Combined TEOAE/ABR is the gold standard for NICU babies which are at risk for auditory neuropathy. Coexisting risk factors are an additional risk factor for HL. (c) 2012 Elsevier Ireland Ltd. All rights reserved.”
“Objectives: To implement a comprehensive service to screen for metabolic syndrome, assess the prevalence of metabolic syndrome, determine the 10-year risk of developing coronary heart disease (CHD), and measure the effectiveness of patient education on lifestyle modifications.
Design: Cross-sectional study.
Setting: Community pharmacy in Pennsylvania
between February 2006 and August 2007. Patients: 239 patients 18 years of age or older with no history of CHD.
Intervention: Participating patients were screened for 4EGI-1 metabolic syndrome, Framingham risk assessment, and medication use. Test results were discussed and patients were educated on metabolic syndrome and lifestyle recommendations. A follow-up survey was administered.
Main outcome measures: Prevalence of metabolic syndrome in the study population, Framingham risk assessment of those with metabolic syndrome, proportion of patients with self-reported lifestyle modifications.
Results: The prevalence of metabolic syndrome in our study population was 36%. The Framingham risk assessment of patients with metabolic syndrome and no known history of diabetes revealed that 65.3% were at low risk, 26.4% were at moderate risk, and 8.3% were at high risk for CHD.